Abstract

Chronic kidney disease (CKD) leads to the development of mineral and skeletal disturbances. They increase the risk of fractures, cardiovascular complications and, in consequence, decrease patients’ lifespan. Wnt/β-catenin pathway plays an important role in the development and homeostasis of the skeleton. The system is tightly regulated by group of inhibitors, such as sclerostin. Sclerostin inhibits bone formation and increases its resorption. There is mounting evidence that sclerostin may take part in the progress of bone and cardiovascular complications among patients with CKD. This review presents the current state of knowledge on the role of sclerostin in bone and cardiovascular disturbances in CKD patients.

References

• 1. Ai M., Heeger S., Bartels C.F., Schelling D.K., Osteoporosis-Pseudoglioma Collaborative Group: Clinical and molecular findings in osteoporosis-pseudoglioma syndrome. Am. J. Hum. Genet., 2005; 77: 741-753
  Google Scholar
• 2. Alem A.M., Sherrard D.J., Gillen D.L., Weiss N.S., Beresford S.A., Heckbert S.R., Wong C., Stehman-Breen C.: Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int., 2000; 58: 396-399
  Google Scholar
• 3. Balcı M., Kırkpantur A., Turkvatan A., Mandıroglu S., Ozturk E., Afsar B.: Sclerostin as new key player in arteriovenous fistula calcification. Herz, 2015; 40: 289-297
  Google Scholar
• 4. Balemans W., Ebeling M., Patel N., Van Hul E., Olson P., Dioszegi M., Lacza C., Wuyts W., Van Den Ende J., Willems P., Paes-Alves A.F., Hill S., Bueno M., Ramos F.J., Tacconi P. wsp.: Increased bone density in sclerosteosis is due to the deficiency of novel secreted protein (SOST). Hum. Mol. Genet., 2001; 10: 537-543
  Google Scholar
• 5. Baron R., Kneissel M.: WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat. Med., 2013; 19: 179-192
  Google Scholar
• 6. Bellido T., Ali A.A., Gubrij I., Plotkin L.I., Fu Q., O’Brien C.A., Manolagas S.C., Jilka R.L.: Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: novel mechanism for hormonal control of osteoblastogenesis. Endocrinology, 2005; 146: 4577-4583
  Google Scholar
• 7. Bonani M., Rodriguez D., Fehr T., Mohebbi N., Brockmann J., Blum M., Graf N., Frey D., Wüthrich R.P.: Sclerostin blood levels before and after kidney transplantation. Kidney Blood Press. Res., 2014; 39: 230-239
  Google Scholar
• 8. Brandenburg V.M., Kramann R., Koos R., Krüger T., Schurgers L., Mühlenbruch G., Hübner S., Gladziwa U., Drechsler C., Ketteler M.: Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: cross-sectional study. BMC Nephrol., 2013; 14: 219
  Google Scholar
• 9. Brunkow M.E., Gardner J.C., Van Ness J., Paeper B.W., Kovacevich B.R., Proll S., Skonier J.E., Zhao L., Sabo P.J., Fu Y., Alisch R.S., Gillett L., Colbert T., Tacconi P., Galas D. wsp.: Bone dysplasia sclerosteosis results from loss of the SOST gene product, novel cystine knot-containing protein. Am. J. Hum. Genet., 2001; 68: 577-589
  Google Scholar
• 10. Cejka D., Herberth J., Branscum A.J., Fardo D.W., Monier-Faugere M.C., Diarra D., Haas M., Malluche H.H.: Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin. J. Am. Soc. Nephrol., 2011; 6: 877-882
  Google Scholar
• 11. Cejka D., Jäger-Lansky A., Kieweg H., Weber M., Bieglmayer C., Haider D.G., Diarra D., Patsch J.M.,Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol. Dial. Transplant., 2012; 27: 226-230 Kainberger F., Bohle B., Haas M.:
  Google Scholar
• 12. Cejka D., Marculescu R., Kozakowski N., Plischke M., Reiter T., Gessl A., Haas M.: Renal elimination of sclerostin increases with declining kidney function. J. Clin. Endocrinol. Metab., 2014; 99: 248-255
  Google Scholar
• 13. Cejka D., Parada-Rodriguez D., Pichler S., Marculescu R., Kramer I., Kneissel M., Gross T., Reisinger A., Pahr D., Monier-Faugere M.C., Haas M., Malluche H.H.: Only minor differences in renal osteodystrophy features between wild-type and sclerostin knockout mice with chronic kidney disease. Kidney Int., 2016; 90: 828-834
  Google Scholar
• 14. Claes K.J., Viaene L., Heye S., Meijers B., d’Haese P., Evenepoel P.: Sclerostin: another vascular calcification inhibitor? J. Clin. Endocrinol. Metab., 2013; 98: 3221-3228
  Google Scholar
• 15. Coco M., Rush H.: Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am. J. Kidney Dis., 2000; 36: 1115-1121
  Google Scholar
• 16. Cohen-Kfir E., Artsi H., Levin A., Abramowitz E., Bajayo A., Gurt I., Zhong L., D’Urso A., Toiber D., Mostoslavsky R., Dresner-Pollak R.: Sirt1 is regulator of bone mass and repressor of Sost encoding for sclerostin, bone formation inhibitor. Endocrinology, 2011; 152: 4514-4524
  Google Scholar
• 17. Cruciat C.M., Niehrs C.: Secreted and transmembrane wnt inhibitors and activators. Cold Spring Harb. Perspect. Biol., 2013; 5: a015081
  Google Scholar
• 18. de Oliveira R.B., Graciolli F.G., dos Reis L.M., Cancela A.L., Cuppari L., Canziani M.E., Carvalho A.B., Jorgetti V., Moysés R.M.: Disturbances of Wnt/β-catenin pathway and energy metabolism in early CKD: effect of phosphate binders. Nephrol. Dial. Transplant., 2013; 28: 2510-2517
  Google Scholar
• 19. Delanaye P., Krzesinski J.M., Warling X., Moonen M., Smelten N., Médart L., Bruyère O., Reginster J.Y., Pottel H., Cavalier E.: Clinical and biological determinants of sclerostin plasma concentration in hemodialysis patients. Nephron Clin. Pract., 2014; 128: 127-134
  Google Scholar
• 20. Desjardins L., Liabeuf S., Oliveira R.B., Louvet L., Kamel S., Lemke H.D., Vanholder R., Choukroun G., Massy Z.A., European Uremic Toxin (EUTox) Work Group: Uremic toxicity and sclerostin in chronic kidney disease patients. Nephrol. Ther., 2014; 10: 463-470
  Google Scholar
• 21. Drake M.T., Farr J.N.: Inhibitors of sclerostin: emerging concepts. Curr. Opin. Rheumatol., 2014; 26: 447-452
  Google Scholar
• 22. Drechsler C., Evenepoel P., Vervloet M.G., Wanner C., Ketteler M., Marx N., Floege J., Dekker F.W., Brandenburg V.M., NECOSAD Study Group: High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. Nephrol. Dial. Transplant., 2015; 30: 288-293
  Google Scholar
• 23. Evenepoel P., Claes K., Viaene L., Bammens B., Meijers B., Naesens M., Sprangers B., Kuypers D.: Decreased circulating sclerostin levels in renal transplant recipients with persistent hyperparathyroidism. Transplantation, 2016; 100: 2188-2193
  Google Scholar
• 24. Evenepoel P., Goffin E., Meijers B., Kanaan N., Bammens B., Coche E., Claes K., Jadoul M.: Sclerostin serum levels and vascular calcification progression in prevalent renal transplant recipients. J. Clin. Endocrinol. Metab., 2015; 100: 4669-4676
  Google Scholar
• 25. Fang Y., Ginsberg C., Seifert M., Agapova O., Sugatani T., Register T.C., Freedman B.I., Monier-Faugere M.C., Malluche H., Hruska K.A.: CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder. J. Am. Soc. Nephrol., 2014; 25: 1760-1773
  Google Scholar
• 26. Fang Y., Ginsberg C., Sugatani T., Monier-Faugere M.C., Malluche H., Hruska K.A.: Early chronic kidney disease-mineral bone disorder stimulates vascular calcification. Kidney Int., 2014; 85: 142-150
  Google Scholar
• 27. Ferreira J.C., Ferrari G.O., Neves K.R., Cavallari R.T., Dominguez W.V., Dos Reis L.M., Graciolli F.G., Oliveira E.C., Liu S., Sabbagh Y., Jorgetti V., Schiavi S., Moysés R.M.: Effects of dietary phosphate on adynamic bone disease in rats with chronic kidney disease – role of sclerostin? PLoS One, 2013; 8: e79721
  Google Scholar
• 28. Galea G.L., Sunters A., Meakin L.B., Zaman G., Sugiyama T., Lanyon L.E., Price J.S.: Sost down-regulation by mechanical strain in human osteoblastic cells involves PGE2 signaling via EP4. FEBS Lett., 2011; 585: 2450-2454
  Google Scholar
• 29. Genetos D.C., Toupadakis C.A., Raheja L.F., Wong A., Papanicolaou S.E., Fyhrie D.P., Loots G.G., Yellowley C.E.: Hypoxia decreases sclerostin expression and increases Wnt signaling in osteoblasts. J. Cell. Biochem., 2010; 110: 457-467
  Google Scholar
• 30. Gonçalves F.L., Elias R.M., dos Reis L.M., Graciolli F.G., Zampieri F.G., Oliveira R.B., Jorgetti V., Moysés R.M.: Serum sclerostin is an independent predictor of mortality in hemodialysis patients. BMC Nephrol., 2014; 15: 190
  Google Scholar
• 31. Gooi J.H., Pompolo S., Karsdal M.A., Kulkarni N.H., Kalajzic I., McAhren S.H., Han B., Onyia J.E., Ho P.W., Gillespie M.T., Walsh N.C., Chia L.Y., Quinn J.M., Martin T.J., Sims N.A.: Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes. Bone, 2010; 46: 1486-1497
  Google Scholar
• 32. Ishimura E., Okuno S., Ichii M., Norimine K., Yamakawa T., Shoji S., Nishizawa Y., Inaba M.: Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients. J. Clin. Endocrinol. Metab., 2014; 99: 4315-4320
  Google Scholar
• 33. Jean G., Chazot C., Bresson E., Zaoui E., Cavalier E.: High serum sclerostin levels are associated with better outcome in haemodialysis patients. Nephron, 2016; 132: 181-190
  Google Scholar
• 34. Johnson M.L., Gong G., Kimberling W., Reckér S.M., Kimmel D.B., Recker R.B.: Linkage of gene causing high bone mass to human chromosome 11 (11q12-13). Am. J. Hum. Genet., 1997; 60: 1326-1332
  Google Scholar
• 35. Kakareko K., Rydzewska-Rosolowska A., Brzosko S., Gozdzikiewicz-Lapinska J., Koc-Zorawska E., Samocik P., Kozlowski R., Mysliwiec M., Naumnik B., Hryszko T.: Renal handling of sclerostin in response to acute glomerular filtration decline. Horm. Metab. Res., 2016; 48: 457-461
  Google Scholar
• 36. Kanbay M., Siriopol D., Saglam M., Kurt Y.G., Gok M., Cetinkaya H., Karaman M., Unal H.U., Oguz Y., Sari S., Eyileten T., Goldsmith D., Vural A., Veisa G., Covic A. wsp.: Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients. J. Clin. Endocrinol. Metab., 2014; 99: E1854-E1861
  Google Scholar
• 37. Kanbay M., Solak Y., Siriopol D., Aslan G., Afsar B., Yazici D., Covic A.: Sclerostin, cardiovascular disease and mortality: systematic review and meta-analysis. Int. Urol. Nephrol., 2016; 48: 2029-2042
  Google Scholar
• 38. Kirkpantur A., Balci M., Turkvatan A., Afsar B.: Serum sclerostin levels, arteriovenous fistula calcification and 2-years all-cause mortality in prevalent hemodialysis patients. Nefrologia, 2016; 36: 24-32
  Google Scholar
• 39. Kramann R., Brandenburg V.M., Schurgers L.J., Ketteler M., Westphal S., Leisten I., Bovi M., Jahnen-Dechent W., Knüchel R., Floege J., Schneider R.K.: Novel insights into osteogenesis and matrix remodelling associated with calcific uraemic arteriolopathy. Nephrol. Dial. Transplant., 2013; 28: 856-868
  Google Scholar
• 40. Kramer I., Loots G.G., Studer A., Keller H., Kneissel M.: Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J. Bone Miner. Res., 2010; 25: 178-189
  Google Scholar
• 41. Kuźniewski M., Fedak D., Dumnicka P., Stępień E., Kuśnierz-Cabala B., Cwynar M., Sułowicz W.: Osteoprotegerin and osteoprotegerin/TRAIL ratio are associated with cardiovascular dysfunction and mortality among patients with renal failure. Adv. Med. Sci., 2016; 61: 269-275
  Google Scholar
• 42. Lee Y.T., Ng H.Y., Chiu T.T., Li L.C., Pei S.N., Kuo W.H., Lee C.T.: Association of bone-derived biomarkers with vascular calcification in chronic hemodialysis patients. Clin. Chim. Acta, 2016; 452: 38-43
  Google Scholar
• 43. Levin A., Bakris G.L., Molitch M., Smulders M., Tian J., Williams L.A., Andress D.L.: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int., 2007; 71: 31-38
  Google Scholar
• 44. Little R.D., Carulli J.P., Del Mastro R.G., Dupuis J., Osborne M., Folz C., Manning S.P., Swain P.M., Zhao S.C., Eustace B., Lappe M.M., Spitzer L., Zweier S., Braunschweiger K., Benchekroun Y. wsp.: mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am. J. Hum. Genet., 2002; 70: 11-19
  Google Scholar
• 45. Loots G.G., Keller H., Leupin O., Murugesh D., Collette N.M., Genetos D.C.: TGF-β regulates sclerostin expression via the ECR5 enhancer. Bone, 2012; 50: 663-669
  Google Scholar
• 46. Lv W., Guan L., Zhang Y., Yu S., Cao B., Ji Y.: Sclerostin as new key factor in vascular calcification in chronic kidney disease stages 3 and 4. Int. Urol. Nephrol., 2016; 48: 2043-2050
  Google Scholar
• 47. MacDonald B.T., Tamai K., He X.: Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev. Cell, 2009; 17: 9-26
  Google Scholar
• 48. Malluche H.H., Davenport D.L., Cantor T., Monier-Faugere M.C.: Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis. Clin. J. Am. Soc. Nephrol., 2014; 9: 1254-1262
  Google Scholar
• 49. Martínez-Moreno J.M., Muñoz-Castañeda J.R., Herencia C., Oca A.M. Estepa J.C., Canalejo R., Rodríguez-Ortiz M.E., Perez-Martinez P., Aguilera-Tejero E., Canalejo A., Rodríguez M., Almadén Y.: In vascular smooth muscle cells paricalcitol prevents phosphate-induced Wnt/β-catenin activation. Am. J. Physiol. Renal Physiol., 2012; 303: F1136-F1144
  Google Scholar
• 50. Moe S., Drüeke T., Cunningham J., Goodman W., Martin K., Olgaard K., Ott S., Sprague S., Lameire N., Eknoyan G., Kidney Disease: Improving Global Outcomes (KDIGO): Definition, evaluation, and classification of renal osteodystrophy: position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int., 2006; 69: 1945-1953
  Google Scholar
• 51. Moe S.M., Chen N.X., Newman C.L., Organ J.M., Kneissel M., Kramer I., Gattone V.H., Allen M.R.: Anti-sclerostin antibody treatment in rat model of progressive renal osteodystrophy. J. Bone Miner. Res., 2015; 30: 499-509
  Google Scholar
• 52. Moldovan D., Rusu C., Kacso I.M., Potra A., Patiu I.M., Gherman-Caprioara M.: Mineral and bone disorders, morbidity and mortality in end-stage renal failure patients on chronic dialysis. Clujul Med., 2016; 89: 94-103
  Google Scholar
• 53. Morena M., Jaussent I., Dupuy A.M., Bargnoux A.S., Kuster N., Chenine L., Leray-Moragues H., Klouche K., Vernhet H., Canaud B., Cristol J.P.: Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications. Nephrol. Dial. Transplant., 2015; 30: 1345-1356
  Google Scholar
• 54. Nowak A., Artunc F., Serra A.L., Pollock E., Krayenbühl P.A., Müller C., Friedrich B.: Sclerostin quo vadis? – is this useful longterm mortality parameter in prevalent hemodialysis patients? Kidney Blood Press. Res., 2015; 40: 266-276
  Google Scholar
• 55. Pelletier S., Confavreux C.B., Haesebaert J., Guebre-Egziabher F., Bacchetta J., Carlier M.C., Chardon L., Laville M., Chapurlat R., London G.M., Lafage-Proust M.H., Fouque D.: Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients? Osteoporos. Int., 2015; 26: 2165-2174
  Google Scholar
• 56. Pelletier S., Dubourg L., Carlier M.C., Hadj-Aissa A., Fouque D.: The relation between renal function and serum sclerostin in adult patients with CKD. Clin. J. Am. Soc. Nephrol., 2013; 8: 819-823
  Google Scholar
• 57. Pereira R.C., Jüppner H., Gales B., Salusky I.B., Wesseling-Perry K.: Osteocytic protein expression response to doxercalciferol therapy in pediatric dialysis patients. PLoS One, 2015; 10: e0120856
  Google Scholar
• 58. Piec I., Washbourne C., Tang J., Fisher E., Greeves J., Jackson S., Fraser W.D.: How accurate is your sclerostin measurement? Comparison between three commercially available sclerostin ELISA kits. Calcif. Tissue Int., 2016; 98: 546-555
  Google Scholar
• 59. Poole K.E., van Bezooijen R.L., Loveridge N., Hamersma H., Papapoulos S.E., Löwik C.W., Reeve J.: Sclerostin is delayed secreted product of osteocytes that inhibits bone formation. FASEB J., 2005; 19: 1842-1844
  Google Scholar
• 60. Qureshi A.R., Olauson H., Witasp A., Haarhaus M., Brandenburg V., Wernerson A., Lindholm B., Söderberg M., Wennberg L., Nordfors L., Ripsweden J., Barany P., Stenvinkel P.: Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification. Kidney Int., 2015; 88: 1356-1364
  Google Scholar
• 61. Register T.C., Hruska K.A., Divers J., Bowden D.W., Palmer N.D., Carr J.J., Wagenknecht L.E., Hightower R.C., Xu J., Smith S.C., Dietzen D.J., Langefeld C.D., Freedman B.I.: Sclerostin is positively associated with bone mineral density in men and women and negatively associated with carotid calcified atherosclerotic plaque in men from the African American-Diabetes Heart Study. J. Clin. Endocrinol. Metab., 2014; 99: 315-321
  Google Scholar
• 62. Robling A.G., Niziolek P.J., Baldridge L.A., Condon K.W., Allen M.R., Alam I., Mantila S.M., Gluhak-Heinrich J., Bellido T.M., Harris S.E., Turner C.H.: Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J. Biol. Chem., 2008; 283: 5866-5875
  Google Scholar
• 63. Roforth M.M., Fujita K., McGregor U.I., Kirmani S., McCready L.K., Peterson J.M., Drake M.T., Monroe D.G., Khosla S.: Effects of age on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in humans. Bone, 2014; 59: 1-6
  Google Scholar
• 64. Rong S., Zhao X., Jin X., Zhang Z., Chen L., Zhu Y., Yuan W.: Vascular calcification in chronic kidney disease is induced by bone morphogenetic protein-2 via mechanism involving the Wnt/β-catenin pathway. Cell. Physiol. Biochem., 2014; 34: 2049-2060
  Google Scholar
• 65. Scialla J.J., Xie H., Rahman M., Anderson A.H., Isakova T., Ojo A., Zhang X., Nessel L., Hamano T., Grunwald J.E., Raj D.S., Yang W., He J., Lash J.P., Go A.S. wsp.: Fibroblast growth factor-23 and cardiovascular events in CKD. J. Am. Soc. Nephrol., 2014; 25: 349-360
  Google Scholar
• 66. Seiler S., Reichart B., Roth D., Seibert E., Fliser D., Heine G.H.: FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol. Dial. Transplant., 2010; 25: 3983-3989
  Google Scholar
• 67. Shanahan C.M., Crouthamel M.H., Kapustin A., Giachelli C.M.: Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ. Res., 2011; 109: 697-711
  Google Scholar
• 68. Sugiyama T., Torio T., Miyajima T., Kim Y.T., Oda H.: Romosozumab and blosozumab: alternative drugs of mechanical strain-related stimulus toward cure for osteoporosis. Front. Endocrinol., 2015; 6: 54
  Google Scholar
• 69. Sutherland M.K., Geoghegan J.C., Yu C., Winkler D.G., Latham J.A.: Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts. Bone, 2004; 35: 448-454
  Google Scholar
• 70. Szulc P., Boutroy S., Vilayphiou N., Schoppet M., Rauner M., Chapurlat R., Hamann C., Hofbauer L.C.: Correlates of bone microarchitectural parameters and serum sclerostin levels in men: the STRAMBO study. J. Bone Miner. Res., 2013; 28: 1760-1770
  Google Scholar
• 71. Thambiah S., Roplekar R., Manghat P., Fogelman I., Fraser W.D., Goldsmith D., Hampson G.: Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif. Tissue Int., 2012; 90: 473-480
  Google Scholar
• 72. Tian E., Zhan F., Walker R., Rasmussen E., Ma Y., Barlogie B., Shaughnessy J.D.Jr.: The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med., 2003; 349: 2483-2494
  Google Scholar
• 73. Ureña P., De Vernejoul M.C.: Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int., 1999; 55: 2141-2156
  Google Scholar
• 74. van Amerongen R., Nusse R.: Towards an integrated view of Wnt signaling in development. Development, 2009; 136: 3205-3214
  Google Scholar
• 75. Viaene L., Behets G.J., Claes K., Meijers B., Blocki F., Brandenburg V., Evenepoel P., D’Haese P.C.: Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis? Nephrol. Dial. Transplant., 2013; 28: 3024-3030
  Google Scholar
• 76. Vincent C., Findlay D.M., Welldon K.J., Wijenayaka A.R., Zheng T.S., Haynes D.R., Fazzalari N.L., Evdokiou A., Atkins G.J.: Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFα induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J. Bone Miner. Res., 2009; 24: 1434-1449
  Google Scholar
• 77. Wang X.R., Yuan L., Zhang J.J., Hao L., Wang D.G.: Serum sclerostin values are associated with abdominal aortic calcification and predict cardiovascular events in patients with chronic kidney disease stages 3-5D. Nephrology, 2017; 22: 286-292
  Google Scholar
• 78. Widelitz R.: Wnt signaling through canonical and non-canonical pathways: recent progress. Growth Factors, 2005; 23: 111-116
  Google Scholar
• 79. Więcek A., Kuczera P., Adamczak M.: Treatment with cinacalcet increases sclerostin concentration in hemodialysed patients with chronic kidney disease and secondary hyperparathyroidism. J. Am. Soc. Nephrol., 2015; 26: 204A
  Google Scholar
• 80. Wijenayaka A.R., Yang D., Prideaux M., Ito N., Kogawa M., Anderson P.H., Morris H.A., Solomon L.B., Loots G.G., Findlay D.M., Atkins G.J.: 1α,25-dihydroxyvitamin D3 stimulates human SOST gene expression and sclerostin secretion. Mol. Cell. Endocrinol., 2015; 413: 157-167
  Google Scholar
• 81. Williams B.O.: Insights into the mechanisms of sclerostin action in regulating bone mass accrual. J. Bone Miner. Res., 2014; 29: 24-28
  Google Scholar
• 82. Yang C.Y., Chang Z.F., Chau Y.P., Chen A., Yang W.C., Yang A.H., Lee O.K.: Circulating Wnt/β-catenin signalling inhibitors and uraemic vascular calcifications. Nephrol. Dial. Transplant., 2015; 30: 1356-1363
  Google Scholar
• 83. Zhu D., Mackenzie N.C., Millán J.L., Farquharson C., MacRae V.E.: The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One, 2011; 6: e19595
  Google Scholar

Full text